Main Article Content


COVID-19 is characterized by the recently identified SARS-CoV-2 coronavirus, that was originally surfaced at Wuhan, China, but soon expanded globally, posing a huge public health threat. In the same way as with severe acute respiratory is mostly a respiratory illness with symptoms such as cough, dyspnea and fever being the most often reported. Causes of acute syndrome (ARDS), septic shock, and death are all possible outcomes for patients who get pneumonia in the most extreme circumstances. Additionally, liver dysfunction has been noted as a frequent symptom, but its clinical importance is unknown, especially in individuals with underlying chronic liver illness. In the wake of the pandemic surge and subsequent lockdown, numerous medical ailments and illnesses have been impacted. Patient care for those with pre-existing liver illness, hepatocellular carcinoma, and those who have undergone or are scheduled to get a liver transplant has been altered because of the early ambiguity and concern about SARS-CoV-2 cross transmission. COVID-19 is a multisystem illness caused by the SARS-CoV-2 virus strain. Pre-existing liver illness may reappear and produce acute liver damage. There have been several studies looking at the effects of COVID-19 on the liver and how it may be used to treat those who already have liver disease. This article summarizes the findings of such investigations.


Severe acute respiratory syndrome (SARS), Middle east respiratory syndrome (MERS-CoV), Coronavirus, Acute respiratory distress syndrome (ARDS), GGT (gamma-glutamyl transferase), SARS-CoV.

Article Details